Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Paresh Patel and Dr. Masoumeh Ghayouri for the second installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode focuses on HER2 testing in biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA), two GI malignancies where HER2 overexpression is increasingly recognized as an important biomarker for targeted therapy.

HER2 has long been a key therapeutic target in breast cancer, but research now shows that HER2 overexpression occurs in up to 30 percent of biliary tract cancers and approximately 20 percent of gastroesophageal adenocarcinomas. As targeted treatment options expand, identifying HER2 status has become a critical step in guiding treatmen ...